bsm-51692M [Primary Antibody]
CCND1 Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: CCND1

Clonality: Monoclonal

Entrez Gene: 595

Swiss Prot: P24385

Source: Recombinant human CCND1.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma (RB)protein family including RB1 and regulates the cell-cycle duringG(1)/S transition. Phosphorylation of RB1 allows dissociation ofthe transcription factor E2F from the RB/E2F complex and thesubsequent transcription of E2F target genes which are responsiblefor the progression through the G(1) phase. Hypophosphorylates RB1in early G(1) phase. Cyclin D-CDK4 complexes are major integratorsof various mitogenenic and antimitogenic signals. Also substratefor SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent mannerand repressing its transcriptional activity. Component of theternary complex, cyclin D1/CDK4/CDKN1B, required for nucleartranslocation and activity of the cyclin D-CDK4 complex.

Size: 100ul

Concentration: 0.5ug/ul

Applications: WB=1:500-2000，

Predicted Molecular Weight: 32


Cross Reactive Species: Human
Mouse

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Wei Wang. et al. Silencing of FAM111B inhibits tumor growth and promotes apoptosis by decreasing AKT activity in ovarian cancer. EXP BIOL MED. ;()Read more>>
  • Ruixue Zhang. et al. The miR-15b-5p/miR-379-3p-FOXO axis regulates cell cycle and apoptosis in scleral remodeling during experimental myopia. J TRANSL MED. 2024; 22: 71Read more>>
VALIDATION IMAGES

Lane 1: MCF-7 cell lysates; Lane 2: HT-1080 cell lysates; Lane 3: L929 cell lysates; Lane 4: NIH/3T3 cell lysates probed with CCND1 Monoclonal Antibody, Unconjugated (bsm-51692M) at 1:2000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.